^
    Back
    Association details:
    Biomarker:NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    idarubicin (DNA replication inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

    Published date:
    11/01/2018
    Excerpt:
    ...study has explored the role of mutation patterns determined by NGS in older AML pts...Pts received one 7+3 course followed by 2 intermediate-dose cytarabine courses…The 49 NPM1mut pts with SRSF2 mutation and/or without adverse co-mutations (FLT3-ITDhighDNMT3A, ASXL1 and NRAS) had a median OS of 49.7 months, defining very low risk...
    DOI:
    10.1182/blood-2018-99-111144
    Trial ID:
    ALFA1200